Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Zoetis Inc Class A (ZTS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 30,812,422
  • Shares Outstanding, K 490,800
  • Annual Sales, $ 4,888 M
  • Annual Income, $ 821,000 K
  • 36-Month Beta 1.03
  • Price/Sales 6.38
  • Price/Cash Flow 25.81
  • Price/Book 19.10

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.92 +3.05%
on 06/13/17
63.85 -1.67%
on 06/20/17
+1.35 (+2.20%)
since 05/23/17
3-Month
52.25 +20.15%
on 04/06/17
63.85 -1.67%
on 06/20/17
+8.98 (+16.69%)
since 03/23/17
52-Week
45.28 +38.65%
on 06/27/16
63.85 -1.67%
on 06/20/17
+14.88 (+31.06%)
since 06/23/16

Most Recent Stories

More News
SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Nexvet Biopharma plc and Encourages Investors to Contact the Firm for Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by...

NVET : 6.69 (unch)
ZTS : 62.78 (-1.15%)
Celgene (CELG) Reports Data on Lupus Drug in Phase II Trial

Celgene Corporation (CELG) announced results from the phase II trial, SLE-001 which evaluated lupus candidate, CC-220, at the Annual European Congress of Rheumatology (EULAR) 2017 in Madrid.

AGIO : 59.18 (+3.07%)
CELG : 134.31 (+0.47%)
VVUS : 1.22 (+5.17%)
ZTS : 62.78 (-1.15%)
Patented Biotechnology Formulations Resulting in New Generation of Animal Healthcare Medications and Treatments

PALM BEACH, Florida, June 14, 2017 /PRNewswire/ --

PETS : 40.47 (-0.57%)
MRK : 66.16 (+0.21%)
LLY : 83.89 (-0.50%)
ZTS : 62.78 (-1.15%)
PTLF : 0.1800 (-16.28%)
PFE : 34.17 (+0.32%)
Patented Biotechnology Formulations Resulting in New Generation of Animal Healthcare Medications and Treatments

The North America animal healthcare market was valued over $10 billion as recent as 2015 and is estimated to possibly exceed to reach over $14 Billion by 2020. A growing veterinarian pet medications advancement...

PETS : 40.47 (-0.57%)
MRK : 66.16 (+0.21%)
LLY : 83.89 (-0.50%)
ZTS : 62.78 (-1.15%)
PTLF : 0.1800 (-16.28%)
PFE : 34.17 (+0.32%)
Ex-Dividend Reminder: Zoetis, Owens & Minor and Community Trust Bancorp

Looking at the universe of stocks we cover at Dividend Channel, on 6/13/17, Zoetis Inc , Owens & Minor, Inc. , and Community Trust Bancorp, Inc.

ZTS : 62.78 (-1.15%)
Adamas Provides Positive Long-term Data on Parkinson's Drug

Adamas Pharmaceuticals, Inc. (ADMS) presented expanded analysis from an ongoing open label phase III study EASE LID 2 on its lead candidate, ADS-5102 extended-release capsules.

VVUS : 1.22 (+5.17%)
ADMS : 17.50 (+4.04%)
ZTS : 62.78 (-1.15%)
UCBJF : 68.6580 (-4.06%)
Zoetis (ZTS) Up 6.4% Since Earnings Report: Can It Continue?

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ZTS : 62.78 (-1.15%)
Jazz Pharma Sleep Disorder Candidate Positive in Phase III

Jazz Pharmaceuticals plc (JAZZ) announced positive efficacy results from studies evaluating its lead pipeline candidate, JZP-110, in adult patients with excessive sleepiness (ES) associated with narcolepsy...

JAZZ : 158.80 (-0.43%)
VVUS : 1.22 (+5.17%)
ZTS : 62.78 (-1.15%)
NVS : 86.34 (unch)
Celgene and Agios Announce Data on Idhifa for Leukemia

Celgene Corporation (CELG) and Agios Pharmaceuticals, Inc. (AGIO) announced new efficacy and safety data on experimental candidate Idhifa (enasidenib).

AGIO : 59.18 (+3.07%)
CELG : 134.31 (+0.47%)
VVUS : 1.22 (+5.17%)
ZTS : 62.78 (-1.15%)
Celgene & Acceleron Complete Enrollment on Thalassemia Drug

Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) announced that the companies have completed target enrollment in the phase III studies, MEDALIST and BELIEVE on pipeline candidate luspatercept....

CELG : 134.31 (+0.47%)
VVUS : 1.22 (+5.17%)
ZTS : 62.78 (-1.15%)
XLRN : 34.10 (+0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services.

See More

Support & Resistance

2nd Resistance Point 63.97
1st Resistance Point 63.37
Last Price 62.78
1st Support Level 62.33
2nd Support Level 61.89

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.